Overview of MITEM PHARMA's Latest Acquisition
MITEM PHARMA, a pharmaceutical lab committed to Medicines of Major Therapeutic Interest (M.I.T.M.), is excited to announce its acquisition of the worldwide rights to DESFERAL® (deferoxamine). This critical drug plays a vital role in the field of hematology. The transaction was made possible thanks to the support of TechLife Capital and MACSF, who understand the significance of these medications for patient care.
Why DESFERAL® Matters in Healthcare
DESFERAL® (deferoxamine) is an injectable treatment for iron overload, a condition that can arise from blood transfusions in patients with diseases such as beta-thalassemia and sickle cell anemia. Being included on the WHO's list of essential medicines reinforces DESFERAL®'s importance as a potentially life-saving therapy.
Collaborating with Financial Partners
The acquisition of DESFERAL® was made possible through the backing of prominent financial partners including TechLife Capital, MACSF, Access Capital Partners, and Swen Capital Partners. Their enthusiasm for MITEM PHARMA stems from its exclusive focus on MITMs, offering essential services to patients worldwide. While the details of the financial arrangements haven’t been revealed, the collective commitment of these partners highlights their dedication to improving healthcare for patients.
MITEM PHARMA’s Mission and Growth Strategy
MITEM PHARMA has positioned itself as an innovative pharmaceutical entity dedicated to refreshing and expanding treatment opportunities for serious health conditions. By pinpointing therapeutic needs and ensuring a steady supply of crucial medical products, along with developing new treatment solutions, MITEM PHARMA aims to provide optimal therapies tailored to each patient's unique requirements.
Global Availability of DESFERAL®
Currently, DESFERAL® is marketed in over 60 countries and is manufactured in Europe, illustrating wide acceptance and its proven effectiveness. Its injectable formulation benefits from a strong safety profile, greatly enhancing its usability and success in clinical settings.
Recognizing the Need for DESFERAL®
Conditions such as beta-thalassemia and sickle cell anemia highlight the healthcare challenges faced by millions worldwide. Beta-thalassemia affects hemoglobin production, while sickle cell anemia results in abnormalities in red blood cell formation. These disorders can lead to severe tissue oxygenation issues and serious vascular complications. Approximately 50 million people are impacted by sickle cell anemia globally, with around 310,000 newborns diagnosed each year, while beta-thalassemia affects around 10 individuals per million.
Commitment to Treating Rare Diseases
With the acquisition of DESFERAL®, MITEM PHARMA is set to enhance its portfolio, which already includes four other MITMs. This acquisition represents a key milestone in MITEM PHARMA’s growth strategy as it aims to establish itself as a leading provider of medications for severe and rare diseases.
Founders' Vision for Future Growth
Claude-Alain CUDENNEC and Eric THIERRY, the founders of MITEM PHARMA, expressed their pride in this acquisition, which underscores their commitment to tackling hereditary and rare diseases. They note the trust that Novartis placed in them through this transaction, emphasizing the professionalism and dedication of the MITEM PHARMA team. They are committed to expanding their international reach to ensure that vital treatments remain accessible for those in need.
Insights from Financial Partners
Jacques ROSSIGNOL and Jean-Max DEMIAUTTE from TechLife Capital shared their satisfaction in supporting MITEM PHARMA as it navigates the intricacies of the pharmaceutical landscape. They reiterated their intention to maintain Novartis's legacy in managing this essential medication and expressed enthusiasm for its ongoing development. Similarly, Sébastien COUVET, Financial Portfolio Manager at MACSF, reaffirmed MACSF's commitment to advancing healthcare through strategic investments in companies like MITEM PHARMA.
About MITEM PHARMA
MITEM PHARMA is dedicated to improving patients' quality of life by ensuring the availability of essential drugs for serious diseases. Collaborating with healthcare professionals and patient advocacy organizations, the lab identifies urgent healthcare requirements and enhances existing treatment options. MITEM PHARMA operates across 15 countries on three continents, adapting to market needs to ensure access to necessary medications in hematology, endocrinology, emergency cardiology, and medical dermatology.
Frequently Asked Questions
What is DESFERAL® and what is it primarily used for?
DESFERAL® (deferoxamine) is an injectable drug used to treat iron overload, especially in patients receiving blood transfusions for conditions like beta-thalassemia and sickle cell anemia.
Why does MITEM PHARMA focus on Medicines of Major Therapeutic Interest?
MITEM PHARMA concentrates on MITMs to address critical healthcare needs by ensuring essential medications are available for serious diseases.
What role do financial partners play in this acquisition?
Financial partners such as TechLife Capital and MACSF play a key role in supporting MITEM PHARMA’s growth through funding and strategic guidance to improve healthcare solutions.
How does MITEM PHARMA ensure the availability of drugs?
MITEM PHARMA collaborates closely with healthcare professionals and patient organizations to identify supply shortages and enhance or develop essential medication formulations, ensuring patient access.
In how many countries can DESFERAL® be found?
DESFERAL® is currently marketed in over 60 countries, showcasing its global presence and acceptance within the medical community.
